Trial · NCT03443973
Adverse events648
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 648
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Arrhythmia | Cardiac disorders | Placebo: DBT | 1 | 474 | 1 |
| other | Arrhythmia | Cardiac disorders | Gantenerumab: DBT | 2 | 501 | 2 |
| other | Arrhythmia | Cardiac disorders | Placebo (DBT) to Gantenerumab: OLE | 1 | 13 | 1 |
| other | Arrhythmia | Cardiac disorders | Gantenerumab (DBT) to Gantenerumab: OLE | 0 | 14 | 0 |
| other | Constipation | Gastrointestinal disorders | Placebo: DBT | 15 | 474 | 16 |
| other | Constipation | Gastrointestinal disorders | Gantenerumab: DBT | 11 | 501 | 12 |
| other | Constipation | Gastrointestinal disorders | Placebo (DBT) to Gantenerumab: OLE | 1 | 13 | 1 |
| other | Constipation | Gastrointestinal disorders | Gantenerumab (DBT) to Gantenerumab: OLE | 0 | 14 | 0 |
| other | Diarrhoea | Gastrointestinal disorders | Placebo: DBT | 25 | 474 | 33 |
| other | Diarrhoea | Gastrointestinal disorders | Gantenerumab: DBT | 39 | 501 | 44 |
| other | Diarrhoea | Gastrointestinal disorders | Placebo (DBT) to Gantenerumab: OLE | 0 | 13 | 0 |
| other | Diarrhoea | Gastrointestinal disorders | Gantenerumab (DBT) to Gantenerumab: OLE | 1 | 14 | 1 |
| other | Oesophagitis | Gastrointestinal disorders | Placebo: DBT | 0 | 474 | 0 |
| other | Oesophagitis | Gastrointestinal disorders | Gantenerumab: DBT | 1 | 501 | 1 |
| other | Oesophagitis | Gastrointestinal disorders | Placebo (DBT) to Gantenerumab: OLE | 0 | 13 | 0 |
| other | Oesophagitis | Gastrointestinal disorders | Gantenerumab (DBT) to Gantenerumab: OLE | 1 | 14 | 1 |
| other | Vomiting | Gastrointestinal disorders | Placebo: DBT | 13 | 474 | 20 |
| other | Vomiting | Gastrointestinal disorders | Gantenerumab: DBT | 22 | 501 | 38 |
| other | Vomiting | Gastrointestinal disorders | Placebo (DBT) to Gantenerumab: OLE | 1 | 13 | 1 |
| other | Vomiting | Gastrointestinal disorders | Gantenerumab (DBT) to Gantenerumab: OLE | 0 | 14 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03443973/events